Callyope vs Elevance Health
Side-by-side comparison of AI visibility scores, market position, and capabilities
Callyope (Paris, AWS Pioneers 2026) raised .41M seed with 8 clinical trials ongoing, using speech AI to detect psychiatric deterioration early and deliver objective data between visits.
About
Callyope is a Paris-based clinical AI company founded to improve outcomes in mental health through passive, continuous monitoring. The company applies speech analysis and machine learning to detect early signals of psychiatric deterioration, enabling clinicians to intervene before crises occur. Its core technology processes vocal biomarkers to track mood, cognition, and behavioral patterns over time without requiring patients to self-report symptoms.\n\nCallyope's platform is designed for integration within clinical workflows, targeting psychiatrists, mental health hospitals, and digital health providers. The product supports remote patient monitoring between visits, generating objective data streams that augment clinician judgment. Unlike consumer wellness apps, Callyope operates within regulated clinical environments and is built to meet the evidentiary standards required for reimbursement and adoption in European and US health systems.\n\nThe company raised a $2.41 million seed round to fund product development and clinical validation. It currently has eight clinical trials ongoing and was selected for the AWS Healthcare Accelerator Pioneers 2026 cohort, reflecting recognition of its technical and scientific rigor. Callyope's pipeline of trial data positions it to pursue regulatory clearance and reimbursement pathways, which would unlock hospital procurement and enterprise mental health contracts at scale.
Indianapolis BCBS managed care (NYSE: ELV) ~$175B FY2024 revenue; Anthem renamed 2022, BCBS exclusive in 14 states, Carelon health services, Medicaid/MA medical cost pressure competing with UnitedHealth and Cigna.
About
Elevance Health, Inc. (formerly Anthem, Inc.) is an Indianapolis, Indiana-based managed care and health services company — publicly traded on the New York Stock Exchange (NYSE: ELV) as an S&P 500 Health Care component — providing health insurance plans under the Blue Cross Blue Shield brand in 14 states (Indiana, Georgia, California, Colorado, Connecticut, Kentucky, Maine, Missouri, Nevada, New Hampshire, New York, Ohio, Virginia, Wisconsin), Medicare Advantage, Medicaid managed care, and commercial employer-sponsored health plans through Carelon (pharmacy and behavioral health services — formerly IngenioRx) to approximately 47 million medical members through approximately 100,000 employees. In fiscal year 2024, Elevance Health reported revenues of approximately $175 billion (predominantly premium revenues from employer-sponsored and government-program health plan members), with operating income under pressure from medical cost increases in the Medicaid segment (post-COVID health utilization normalization causing medical costs to exceed Medicaid actuarial pricing expectations set during the pandemic period of reduced care utilization). CEO Gail Boudreaux has executed the company's transformation from Anthem to Elevance Health (rebranded June 2022) — reflecting the broadened value proposition beyond health insurance into health services: Carelon Services (behavioral health, pharmacy benefit management, utilization management, home health services for both Elevance and external health plan clients) represents the strategy of building a health services ecosystem that retains value within the Elevance enterprise rather than paying external PBMs, behavioral health managers, and care management vendors.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.